FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Bruce Baguley

Research Profile

Chemicals & Drugs

Living Beings

Anatomy

Tumor Cells, Cultured

Disorders

Concepts & Ideas

Procedures

Co-author Network

Publications

TOP 3
Clare J Stones; Graeme J Finlay; Wayne R Joseph; Ji Eun Kim; Euphemia Leung; Elaine S Marshall; Andrew N Shelling; Bruce C Baguley
Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors.
Euphemia Leung; Gordon W Rewcastle; Rhonda J Rosengren; Wayne R Joseph; Lesley Larsen; Bruce C Baguley
Identification of cyclohexanone derivatives that act as catalytic inhibitors of topoisomerase I: effects on tamoxifen-resistant MCF-7 cancer cells.
Liene Daukste; Bruce C Baguley; Britta Basse; David J N Wall
Mathematical determination of cell population doubling times for multiple cell lines.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Bruce Baguley (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Clare J Stones; Graeme J Finlay; Wayne R Joseph; Ji Eun Kim; Euphemia Leung; Elaine S Marshall; Andrew N Shelling; Bruce C Baguley
Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors.
Frontiers in genetics 2013;4():66.
2012: Euphemia Leung; Gordon W Rewcastle; Rhonda J Rosengren; Wayne R Joseph; Lesley Larsen; Bruce C Baguley
Identification of cyclohexanone derivatives that act as catalytic inhibitors of topoisomerase I: effects on tamoxifen-resistant MCF-7 cancer cells.
Investigational new drugs 2012;30(6):2103-12.
2012: Liene Daukste; Bruce C Baguley; Britta Basse; David J N Wall
Mathematical determination of cell population doubling times for multiple cell lines.
Bulletin of mathematical biology 2012;74(10):2510-34.
2012: Hamish S Sutherland; William A Denny; Angela Ding; Catherine Gilchrist; Debra Greenhalgh; In Young Hwang; Wayne R Joseph; Philip Kestell; Brent S Lindsay; Elaine S Marshall; Emma Richardson; Bruce C Baguley
Therapeutic reactivation of mutant p53 protein by quinazoline derivatives.
Investigational new drugs 2012;30(5):2035-45.
2012: Pradeep Lukka; James W Paxton; Philip Kestell; Bruce C Baguley
Comparison of a homologous series of benzonaphthyridine anti-cancer agents in mice: divergence between tumour and plasma pharmacokinetics.
Cancer chemotherapy and pharmacology 2012;70(1):151-60.
2012: Pradeep Lukka; James W Paxton; Graham J Atwell; Philip Kestell; Bruce C Baguley
A rapid LC-MS/MS method for the quantitation of a series of benzonaphthyridine derivatives: application to in vivo pharmacokinetic and lipophilicity studies in drug development.
Journal of pharmaceutical and biomedical analysis 2012;63():9-16.
2012: Ji Eun Kim; Euphemia Leung; Wayne A Phillips; Andrew N Shelling; Peter R Shepherd; Clare Stones; Graeme J Finlay; Wayne R Joseph; Bruce C Baguley
Comparison of growth factor signalling pathway utilisation in cultured normal melanocytes and melanoma cell lines.
BMC cancer 2012;12():141.
2011: Ying Yi Chen; Graeme J Finlay; James A Kirker; Elaine S Marshall; Emma Richardson; Bruce C Baguley
In vivo and in vitro assessment of the action of SN 28049, a benzonaphthyridine derivative targeting topoisomerase II, on the murine Colon 38 carcinoma.
Investigational new drugs 2011;29(6):1504-10.
2011: Gordon W Rewcastle; Ripudaman Singh; Bruce C Baguley; Christina M Buchanan; William A Denny; Jack U Flanagan; Raphael Frederick; Swarna A Gamage; Stephen M F Jamieson; Jackie D Kendall; Philip Kestell; Sharada Kolekar; Woo-Jeong Lee; Claire L Lill; Elaine S Marshall; Peter R Shepherd
Synthesis and biological evaluation of novel analogues of the pan class I phosphatidylinositol 3-kinase (PI3K) inhibitor 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474).
Journal of medicinal chemistry 2011;54(20):7105-26.
2011: Catherine J Drummond; Graeme J Finlay; Elaine S Marshall; Emma Richardson; Laura Broome; Bruce C Baguley
Action of SN 28049, a new DNA binding topoisomerase II-directed antitumour drug: comparison with doxorubicin and etoposide.
Investigational new drugs 2011;29(5):1102-10.
2011: Geoffrey A Charters; Andrew N Shelling; Clare J Stones; Bruce C Baguley; Graeme J Finlay
Centrosomal dysregulation in human metastatic melanoma cell lines.
Cancer genetics 2011;204(9):477-85.
2011: Stephen Jamieson; Jackie D Kendall; Sharada Kolekar; Woo-Jeong Lee; Gordon W Rewcastle; Bruce C Baguley; Christina Buchanan; William A Denny; James Dickson; Jack U Flanagan; Ripudaman Singh; Peter R Shepherd
A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types.
The Biochemical journal 2011;438(1):53-62.
2011: Euphemia Leung; Ji Eun Kim; Gordon W Rewcastle; Graeme J Finlay; Bruce C Baguley
Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells.
Cancer biology & therapy 2011;11(11):938-46.
2011: Bruce C Baguley
Preclinical efficacy of vascular disrupting agents in non-small-cell lung cancer.
Clinical lung cancer 2011;12(2):81-6.
2011: Bruce C Baguley
The paradox of cancer cell apoptosis.
Frontiers in bioscience : a journal and virtual library 2011;16():1759-67.
2010: Bruce C Baguley; Dietmar W Siemann
Temporal aspects of the action of ASA404 (vadimezan; DMXAA).
Expert opinion on investigational drugs 2010;19(11):1413-25.
2010: Bruce C Baguley
Multiple drug resistance mechanisms in cancer.
Molecular biotechnology 2010;46(3):308-16.
2010: Bruce C Baguley; Mark J McKeage
ASA404: a tumor vascular-disrupting agent with broad potential for cancer therapy.
Future oncology (London, England) 2010;6(10):1537-43.
2010: In Young Hwang; Bruce C Baguley; Lai-Ming Ching; Catherine A Gilchrist
The ubiquitin-proteasome system is inhibited by p53 protein expression in human ovarian cancer cells.
Cancer letters 2010;294(1):82-90.
2010: Euphemia Leung; Nagarajan Kannan; Geoffrey W Krissansen; Michael P Findlay; Bruce C Baguley
MCF-7 breast cancer cells selected for tamoxifen resistance acquire new phenotypes differing in DNA content, phospho-HER2 and PAX2 expression, and rapamycin sensitivity.
Cancer biology & therapy 2010;9(9):717-24.
2010: Pradeep B Lukka; James W Paxton; Philip Kestell; Bruce C Baguley
Pharmacokinetics and distribution of SN 28049, a novel DNA binding anticancer agent, in mice.
Cancer chemotherapy and pharmacology 2010;65(6):1145-52.
2010: Mark J McKeage; Bruce C Baguley
Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer.
Cancer 2010;116(8):1859-71.
2010: B Basse; Wayne R Joseph; Elaine S Marshall; Bruce C Baguley
Analysis of radiation-induced changes to human melanoma cultures using a mathematical model.
Cell proliferation 2010;43(2):139-46.
2010: Srinivas Ganta; Puneet Sharma; James W Paxton; Bruce C Baguley; Sanjay Garg
Pharmacokinetics and pharmacodynamics of chlorambucil delivered in long-circulating nanoemulsion.
Journal of drug targeting 2010;18(2):125-33.
2010: Bruce C Baguley
Multidrug resistance in cancer.
Methods in molecular biology (Clifton, N.J.) 2010;596():1-14.
2009: Anassuya Ramachandran; Elaine S Marshall; Donald R Love; Bruce C Baguley; Andrew N Shelling
Activin is a potent growth suppressor of epithelial ovarian cancer cells.
Cancer letters 2009;285(2):157-65.
2009: Liene Daukste; Britta Basse; Bruce C Baguley; David J N Wall
Using a stem cell and progeny model to illustrate the relationship between cell cycle times of in vivo human tumour cell tissue populations, in vitro primary cultures and the cell lines derived from them.
Journal of theoretical biology 2009;260(4):563-71.
2009: L-C Steve Wang; Lai-Ming Ching; James W Paxton; Philip Kestell; Rachel Sutherland; L Zhuang; Bruce C Baguley
Enhancement of the action of the antivascular drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA; ASA404) by non-steroidal anti-inflammatory drugs.
Investigational new drugs 2009;27(3):280-4.
2009: Srinivas Ganta; James W Paxton; Bruce C Baguley; Sanjay Garg
Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery.
International journal of pharmaceutics 2009;367(1-2):179-86.
2008: Pradeep Lukka; Philip Kestell; James W Paxton; Bruce C Baguley
Development and validation of a liquid chromatography-mass spectrometry (LC-MS) assay for the determination of the anti-cancer agent N-[2-(dimethylamino)ethyl]-2,6-dimethyl-1-oxo-1,2-dihydrobenzo[b]-1,6-naphthyridine-4-carboxamide (SN 28049).
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2008;875(2):368-72.
2008: David J Bridewell; Andrew C G Porter; Graeme J Finlay; Bruce C Baguley
The role of topoisomerases and RNA transcription in the action of the antitumour benzonaphthyridine derivative SN 28049.
Cancer chemotherapy and pharmacology 2008;62(5):753-62.
2008: Srinivas Ganta; James W Paxton; Bruce C Baguley; Sanjay Garg
Pharmacokinetics and pharmacodynamics of chlorambucil delivered in parenteral emulsion.
International journal of pharmaceutics 2008;360(1-2):115-21.
2008: Jing Li; Michael B Jameson; Bruce C Baguley; Roberto Pili; Sharyn D Baker
Population pharmacokinetic-pharmacodynamic model of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid in cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(7):2102-10.
2008: Francisco Chung; Jenny Liu; Lai-Ming Ching; Bruce C Baguley
Consequences of increased vascular permeability induced by treatment of mice with 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and thalidomide.
Cancer chemotherapy and pharmacology 2008;61(3):497-502.
2008: Bruce C Baguley; Elaine S Marshall
The use of human tumour cell lines in the discovery of new cancer chemotherapeutic drugs.
Expert opinion on drug discovery 2008;3(2):153-61.
2008: Johnson J Liu; Peter Galettis; Alistair Farr; Lenushka Maharaj; Hasitha Samarasinha; Adam C McGechan; Bruce C Baguley; Richard J Bowen; Susan J Berners-Price; Mark J McKeage
In vitro antitumour and hepatotoxicity profiles of Au(I) and Ag(I) bidentate pyridyl phosphine complexes and relationships to cellular uptake.
Journal of inorganic biochemistry 2008;102(2):303-10.
2008: Srinivas Ganta; James W Paxton; Bruce C Baguley; Sanjay Garg
Development and validation of bioanalytical method for the determination of asulacrine in plasma by liquid chromatography.
Journal of pharmaceutical and biomedical analysis 2008;46(2):386-90.
2007: Jackie D Kendall; Gordon W Rewcastle; Raphael Frederick; Claire Mawson; William A Denny; Elaine S Marshall; Bruce C Baguley; Claire Chaussade; Shaun P Jackson; Peter R Shepherd
Synthesis, biological evaluation and molecular modelling of sulfonohydrazides as selective PI3K p110alpha inhibitors.
Bioorganic & medicinal chemistry 2007;15(24):7677-87.
2007: Liangli Zhao; Elaine S Marshall; Lloyd R Kelland; Bruce C Baguley
Evidence for the involvement of p38 MAP kinase in the action of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Investigational new drugs 2007;25(3):271-6.
2007: Michael B Jameson; Bruce C Baguley; Philip Kestell; Liangli Zhao; James W Paxton; Paul I Thompson; S Waller
Pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (AS1404), a novel vascular disrupting agent, in phase I clinical trial.
Cancer chemotherapy and pharmacology 2007;59(5):681-7.
2007: Johnson J Liu; Lai-Ming Ching; Michael Goldthorpe; Rachel Sutherland; Bruce C Baguley; James A Kirker; Mark J McKeage
Antitumour action of 5,6-dimethylxanthenone-4-acetic acid in rats bearing chemically induced primary mammary tumours.
Cancer chemotherapy and pharmacology 2007;59(5):661-9.
2007: See-Tarn Woon; Sandy S C Hung; Derek C F Wu; Mary Ann Schooltink; Rachel Sutherland; Bruce C Baguley; Qi Chen; Lawrence W Chamley; Lai-Ming Ching
NF-kappaB-independent induction of endothelial cell apoptosis by the vascular disrupting agent DMXAA.
Anticancer research 2007;27(1A):327-34.
2006: Mark J McKeage; Peter Fong; Mark Jeffery; Bruce C Baguley; Philip Kestell; Miroslav Ravic; Michael B Jameson
5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(6):1776-84.
2006: Swarna A Gamage; Gordon W Rewcastle; Bruce C Baguley; Peter A Charlton; William A Denny
Phenazine-1-carboxamides: structure-cytotoxicity relationships for 9-substituents and changes in the H-bonding pattern of the cationic side chain.
Bioorganic & medicinal chemistry 2006;14(4):1160-8.
2006: Bruce C Baguley
Tumor stem cell niches: a new functional framework for the action of anticancer drugs.
Recent patents on anti-cancer drug discovery 2006;1(1):121-7.
2006: Liang-Chuan S Wang; See-Tarn Woon; Bruce C Baguley; Lai-Ming Ching
Inhibition of DMXAA-induced tumor necrosis factor production in murine splenocyte cultures by NF-kappaB inhibitors.
Oncology research 2006;16(1):1-14.
2005: Liangli Zhao; Lai-Ming Ching; Philip Kestell; Lloyd R Kelland; Bruce C Baguley
Mechanisms of tumor vascular shutdown induced by 5,6-dimethylxanthenone-4-acetic acid (DMXAA): Increased tumor vascular permeability.
International journal of cancer. Journal international du cancer 2005;116(2):322-6.
2005: Britta Basse; Bruce C Baguley; Elaine S Marshall; Graeme C Wake; David J N Wall
Modelling the flow [corrected] cytometric data obtained from unperturbed human tumour cell lines: parameter fitting and comparison.
Bulletin of mathematical biology 2005;67(4):815-30.
2005: See-Tarn Woon; Charu B Reddy; Catherine J Drummond; Mary Ann Schooltink; Bruce C Baguley; Claudine Kieda; Lai-Ming Ching
A comparison of the ability of DMXAA and xanthenone analogues to activate NF-kappaB in murine and human cell lines.
Oncology research 2005;15(7-8):351-64.
2005: Bruce C Baguley; Elaine Marshall
Do negative feedback oscillations drive variations in the length of the tumor cell division cycle?
Oncology research 2005;15(6):291-4.
2004: Britta Basse; Bruce C Baguley; Elaine S Marshall; Wayne R Joseph; Bruce van Brunt; Graeme C Wake; David J N Wall
Modelling cell death in human tumour cell lines exposed to the anticancer drug paclitaxel.
Journal of mathematical biology 2004;49(4):329-57.
2004: Shufeng Zhou; Xia Feng; Philip Kestell; Bruce C Baguley; James W Paxton
Determination of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid and its acyl glucuronide in Caco-2 monolayers by liquid chromatography with fluorescence detection: application to transport studies.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2004;809(1):87-97.
2004: Francisco Chung; Jun Lu; Brian Palmer; Philip Kestell; Peter Browett; Bruce C Baguley; Malcolm D Tingle; Lai-Ming Ching
Thalidomide pharmacokinetics and metabolite formation in mice, rabbits, and multiple myeloma patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(17):5949-56.
2004: Jun Lu; Nuala A Helsby; Brian Palmer; Malcolm D Tingle; Bruce C Baguley; Philip Kestell; Lai-Ming Ching
Metabolism of thalidomide in liver microsomes of mice, rabbits, and humans.
The Journal of pharmacology and experimental therapeutics 2004;310(2):571-7.
2004: Britta Basse; Bruce C Baguley; Elaine S Marshall; Graeme C Wake; David J N Wall
Modelling cell population growth with applications to cancer therapy in human tumour cell lines.
Progress in biophysics and molecular biology 2004;85(2-3):353-68.
2004: Francisco Chung; Liang-Chuan S Wang; Philip Kestell; Bruce C Baguley; Lai-Ming Ching
Modulation of thalidomide pharmacokinetics by cyclophosphamide or 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice: the role of tumour necrosis factor.
Cancer chemotherapy and pharmacology 2004;53(5):377-83.
2004: Bruce C Baguley; Elaine S Marshall
In vitro modelling of human tumour behaviour in drug discovery programmes.
European journal of cancer (Oxford, England : 1990) 2004;40(6):794-801.
2004: Liang-Chuan S Wang; Charu B Reddy; Bruce C Baguley; Philip Kestell; Rachel Sutherland; Lai-Ming Ching
Induction of tumour necrosis factor and interferon-gamma in cultured murine splenocytes by the antivascular agent DMXAA and its metabolites.
Biochemical pharmacology 2004;67(5):937-45.
2004: Lai-Ming Ching; S Zwain; Bruce C Baguley
Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice.
British journal of cancer 2004;90(4):906-10.
2004: Elaine S Marshall; Bruce C Baguley; John H L Matthews; Chakiath C Jose; Christopher E Furneaux; James H F Shaw; James A Kirker; Randall P Morton; Julian B White; Michael L Rice; Richard J Isaacs; Richard Coutts; John R Whittaker
Estimation of radiation-induced interphase cell death in cultures of human tumor material and in cell lines.
Oncology research 2004;14(6):297-304.
2003: Liangli Zhao; Lai-Ming Ching; Philip Kestell; Bruce C Baguley
Improvement of the antitumor activity of intraperitoneally and orally administered 5,6-dimethylxanthenone-4-acetic acid by optimal scheduling.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(17):6545-50.
2003: Bruce C Baguley; Laurence P G Wakelin; Jason D Jacintho; Peter Kovacic
Mechanisms of action of DNA intercalating acridine-based drugs: how important are contributions from electron transfer and oxidative stress?
Current medicinal chemistry 2003;10(24):2643-9.
2003: Britta Basse; Bruce C Baguley; Elaine S Marshall; Wayne R Joseph; Bruce van Brunt; Graeme C Wake; David J N Wall
A mathematical model for analysis of the cell cycle in cell lines derived from human tumors.
Journal of mathematical biology 2003;47(4):295-312.
2003: S M F Jamieson; Jenny Liu; T Hsu; Bruce C Baguley; Mark J McKeage
Paclitaxel induces nucleolar enlargement in dorsal root ganglion neurons in vivo reducing oxaliplatin toxicity.
British journal of cancer 2003;88(12):1942-7.
2003: Michael B Jameson; Paul I Thompson; Bruce C Baguley; Barrie D Evans; Vernon J Harvey; D J Porter; MR McCrystal; M Small; K Bellenger; Lindsey Gumbrell; Gavin Halbert; Philip Kestell
Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent.
British journal of cancer 2003;88(12):1844-50.
2003: Shufeng Zhou; Philip Kestell; Bruce C Baguley; James W Paxton
Preclinical factors affecting the interindividual variability in the clearance of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid.
Biochemical pharmacology 2003;65(11):1853-65.
2003: Jun Lu; Brian Palmer; Philip Kestell; Peter Browett; Bruce C Baguley; George Muller; Lai-Ming Ching
Thalidomide metabolites in mice and patients with multiple myeloma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(5):1680-8.
2003: See-Tarn Woon; S Zwain; Mary Ann Schooltink; A L Newth; Bruce C Baguley; Lai-Ming Ching
NF-kappa B activation in vivo in both host and tumour cells by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
European journal of cancer (Oxford, England : 1990) 2003;39(8):1176-83.
2003: Bruce C Baguley
Antivascular therapy of cancer: DMXAA.
The lancet oncology 2003;4(3):141-8.
2003: Francisco Chung; Brian Palmer; George W Muller; Hon-Wah Man; Philip Kestell; Bruce C Baguley; Lai-Ming Ching
Effect of 3-fluorothalidomide and 3-methylthalidomide enantiomers on tumor necrosis factor production and antitumor responses to the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Oncology research 2003;14(2):75-82.
2003: William A Denny; Bruce C Baguley
Dual topoisomerase I/II inhibitors in cancer therapy.
Current topics in medicinal chemistry 2003;3(3):339-53.
2003: Shufeng Zhou; Philip Kestell; Bruce C Baguley; James W Paxton
Preclinical factors influencing the relative contributions of Phase I and II enzymes to the metabolism of the experimental anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid.
Biochemical pharmacology 2003;65(1):109-20.
2003: Bruce C Baguley; Elaine S Marshall; Timothy I Christmas
Cultures of surgical material from lung cancers. A kinetic approach.
Methods in molecular medicine 2003;74():527-44.
2002: Bruce C Baguley; Lai-Ming Ching
DMXAA: an antivascular agent with multiple host responses.
International journal of radiation oncology, biology, physics 2002;54(5):1503-11.
2002: Bruce C Baguley; William Wilson
Potential of DMXAA combination therapy for solid tumors.
Expert review of anticancer therapy 2002;2(5):593-603.
2002: Qi Ding; Philip Kestell; Bruce C Baguley; Brian Palmer; James W Paxton; George Muller; Lai-Ming Ching
Potentiation of the antitumour effect of cyclophosphamide in mice by thalidomide.
Cancer chemotherapy and pharmacology 2002;50(3):186-92.
2002: Liangli Zhao; Lai-Ming Ching; Philip Kestell; Bruce C Baguley
The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice.
British journal of cancer 2002;87(4):465-70.
2002: Shufeng Zhou; Philip Kestell; Bruce C Baguley; James W Paxton
5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy.
Investigational new drugs 2002;20(3):281-95.
2002: Lai-Ming Ching; Z Cao; Claudine Kieda; S Zwain; Michael B Jameson; Bruce C Baguley
Induction of endothelial cell apoptosis by the antivascular agent 5,6-Dimethylxanthenone-4-acetic acid.
British journal of cancer 2002;86(12):1937-42.
2002: See-Tarn Woon; Bruce C Baguley; Brian Palmer; John D Fraser; Lai-Ming Ching
Uptake of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and activation of NF-kappaB in human tumor cell lines.
Oncology research 2002;13(2):95-101.
2002: Bruce C Baguley
Novel strategies for overcoming multidrug resistance in cancer.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 2002;16(2):97-103.
2002: Prakash Mistry; Alistair J Stewart; Wendy Dangerfield; Mark Baker; Chris Liddle; Douglas Bootle; Bettina Kofler; Deanne Laurie; William A Denny; Bruce C Baguley; Peter A Charlton
In vitro and in vivo characterization of XR11576, a novel, orally active, dual inhibitor of topoisomerase I and II.
Anti-cancer drugs 2002;13(1):15-28.
2002: Liangli Zhao; Philip Kestell; Lai-Ming Ching; Bruce C Baguley
Oral activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice.
Cancer chemotherapy and pharmacology 2002;49(1):20-6.
2001: David J Bridewell; Graeme J Finlay; Bruce C Baguley
Topoisomerase I/II selectivity among derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA).
Anti-cancer drug design 2001;16(6):317-24.
2001: Philip Kestell; Liangli Zhao; Michael B Jameson; Michael R L Stratford; Lisa K Folkes; Bruce C Baguley
Measurement of plasma 5-hydroxyindoleacetic acid as a possible clinical surrogate marker for the action of antivascular agents.
Clinica chimica acta; international journal of clinical chemistry 2001;314(1-2):159-66.
2001: Mark J McKeage; T Hsu; D Screnci; G Haddad; Bruce C Baguley
Nucleolar damage correlates with neurotoxicity induced by different platinum drugs.
British journal of cancer 2001;85(8):1219-25.
2001: Martin Philpott; Lai-Ming Ching; Bruce C Baguley
The antitumour agent 5,6-dimethylxanthenone-4-acetic acid acts in vitro on human mononuclear cells as a co-stimulator with other inducers of tumour necrosis factor.
European journal of cancer (Oxford, England : 1990) 2001;37(15):1930-7.
2001: Bruce C Baguley
Small-molecule cytokine inducers causing tumor necrosis.
Current opinion in investigational drugs (London, England : 2000) 2001;2(7):967-75.
2001: Liangli Zhao; Philip Kestell; Martin Philpott; Lai-Ming Ching; L Zhuang; Bruce C Baguley
Effects of the serotonin receptor antagonist cyproheptadine on the activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Cancer chemotherapy and pharmacology 2001;47(6):491-7.
2001: Kevin O Hicks; Frederik Pruijn; Bruce C Baguley; William Wilson
Extravascular transport of the DNA intercalator and topoisomerase poison N-[2-(Dimethylamino)ethyl]acridine-4-carboxamide (DACA): diffusion and metabolism in multicellular layers of tumor cells.
The Journal of pharmacology and experimental therapeutics 2001;297(3):1088-98.
2001: S F Zhou; James W Paxton; Malcolm D Tingle; Philip Kestell; Michael B Jameson; Paul I Thompson; Bruce C Baguley
Identification and reactivity of the major metabolite (beta-1-glucuronide) of the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in humans.
Xenobiotica; the fate of foreign compounds in biological systems 2001;31(5):277-93.
2001: Swarna A Gamage; Julie A Spicer; Graeme J Finlay; Alistair J Stewart; Peter A Charlton; Bruce C Baguley; William A Denny
Dicationic bis(9-methylphenazine-1-carboxamides): relationships between biological activity and linker chain structure for a series of potent topoisomerase targeted anticancer drugs.
Journal of medicinal chemistry 2001;44(9):1407-15.
2001: Alistair J Stewart; Prakash Mistry; Wendy Dangerfield; Douglas Bootle; M Baker; B Kofler; S Okiji; Bruce C Baguley; William A Denny; Peter A Charlton
Antitumor activity of XR5944, a novel and potent topoisomerase poison.
Anti-cancer drugs 2001;12(4):359-67.
2001: Z Cao; Bruce C Baguley; Lai-Ming Ching
Interferon-inducible protein 10 induction and inhibition of angiogenesis in vivo by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Cancer research 2001;61(4):1517-21.
2000: Julie A Spicer; Swarna A Gamage; Gordon W Rewcastle; Graeme J Finlay; David J Bridewell; Bruce C Baguley; William A Denny
Bis(phenazine-1-carboxamides): structure-activity relationships for a new class of dual topoisomerase I/II-directed anticancer drugs.
Journal of medicinal chemistry 2000;43(7):1350-8.
2000: D Screnci; Mark J McKeage; Peter Galettis; Trevor W Hambley; Brian Palmer; Bruce C Baguley
Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs.
British journal of cancer 2000;82(4):966-72.
2000: C Lai-Ming; William Wilson; Bruce C Baguley
Inhibition of tumor blood flow.
Methods in molecular medicine 2000;25():133-57.
2000: J Parmar; Elaine S Marshall; G A Charters; KM Holdaway; Andrew N Shelling; Bruce C Baguley
Radiation-induced cell cycle delays and p53 status of early passage melanoma cell lines.
Oncology research 2000;12(3):149-55.
2000: Mark J McKeage; S J Berners-Price; Peter Galettis; R J Bowen; W Brouwer; L Ding; L Zhuang; Bruce C Baguley
Role of lipophilicity in determining cellular uptake and antitumour activity of gold phosphine complexes.
Cancer chemotherapy and pharmacology 2000;46(5):343-50.
2000: Philip Kestell; Liangli Zhao; Bruce C Baguley; Brian Palmer; George Muller; James W Paxton; Lai-Ming Ching
Modulation of the pharmacokinetics of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice by thalidomide.
Cancer chemotherapy and pharmacology 2000;46(2):135-41.
2000: Graeme J Finlay; Bruce C Baguley
Effects of protein binding on the in vitro activity of antitumour acridine derivatives and related anticancer drugs.
Cancer chemotherapy and pharmacology 2000;45(5):417-22.
1999: Lai-Ming Ching; D Goldsmith; Wayne R Joseph; Heinrich Korner; J D Sedgwick; Bruce C Baguley
Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice.
Cancer research 1999;59(14):3304-7.
1999: Swarna A Gamage; Julie A Spicer; Graham J Atwell; Graeme J Finlay; Bruce C Baguley; William A Denny
Structure-activity relationships for substituted bis(acridine-4-carboxamides): a new class of anticancer agents.
Journal of medicinal chemistry 1999;42(13):2383-93.
1999: Julie A Spicer; Swarna A Gamage; Graham J Atwell; Graeme J Finlay; Bruce C Baguley; William A Denny
Dimeric analogues of non-cationic tricyclic aromatic carboxamides are a new class of cytotoxic agents.
Anti-cancer drug design 1999;14(3):281-9.
1999: A Haldane; Graeme J Finlay; Michael Hay; William A Denny; Bruce C Baguley
Cellular uptake of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA).
Anti-cancer drug design 1999;14(3):275-80.
1999: Z Cao; Wayne R Joseph; WL Browne; Kathleen G Mountjoy; Brian Palmer; Bruce C Baguley; Lai-Ming Ching
Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid.
British journal of cancer 1999;80(5-6):716-23.
1999: Julie A Spicer; Graeme J Finlay; Bruce C Baguley; L Velea; David E Graves; William A Denny
5,7-Disubstituted analogues of the mixed topoisomerase I/II poison N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA): DNA binding and patterns of cytotoxicity.
Anti-cancer drug design 1999;14(1):37-45.
1999: Wayne R Joseph; Z Cao; Kathleen G Mountjoy; Elaine S Marshall; Bruce C Baguley; Lai-Ming Ching
Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy.
Cancer research 1999;59(3):633-8.
1999: Mark J McKeage; G G Haddad; L Ding; Peter Galettis; D Screnci; L Zhuang; Bruce C Baguley
Neuroprotective interactions in rats between paclitaxel and cisplatin.
Oncology research 1999;11(6):287-93.
1999: Graeme J Finlay; Graham J Atwell; Bruce C Baguley
Inhibition of the action of the topoisomerase II poison amsacrine by simple aniline derivatives: evidence for drug-protein interactions.
Oncology research 1999;11(6):249-54.
1999: Bruce C Baguley; Elaine S Marshall; Graeme J Finlay
Short-term cultures of clinical tumor material: potential contributions to oncology research.
Oncology research 1999;11(3):115-24.
1999: P C Schofield; IG Robertson; James W Paxton; MR McCrystal; Barrie D Evans; Philip Kestell; Bruce C Baguley
Metabolism of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in cancer patients undergoing a phase I clinical trial.
Cancer chemotherapy and pharmacology 1999;44(1):51-8.
1999: Philip Kestell; I C Dunlop; MR McCrystal; Barrie D Evans; James W Paxton; R S Gamage; Bruce C Baguley
Plasma pharmacokinetics of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in a phase I trial.
Cancer chemotherapy and pharmacology 1999;44(1):45-50.
1999: MR McCrystal; Barrie D Evans; Vernon J Harvey; Paul I Thompson; D J Porter; Bruce C Baguley
Phase I study of the cytotoxic agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide.
Cancer chemotherapy and pharmacology 1999;44(1):39-44.
1999: Philip Kestell; James W Paxton; Gordon W Rewcastle; I Dunlop; Bruce C Baguley
Plasma disposition, metabolism and excretion of the experimental antitumour agent 5,6-dimethylxanthenone-4-acetic acid in the mouse, rat and rabbit.
Cancer chemotherapy and pharmacology 1999;43(4):323-30.
1999: David J Bridewell; Graeme J Finlay; Bruce C Baguley
Mechanism of cytotoxicity of N-[2-(dimethylamino)ethyl] acridine-4-carboxamide and of its 7-chloro derivative: the roles of topoisomerases I and II.
Cancer chemotherapy and pharmacology 1999;43(4):302-8.
1998: WL Browne; William Wilson; Bruce C Baguley; Lai-Ming Ching
Suppression of serum tumour necrosis factor-alpha by thalidomide does not lead to reversal of tumour vascular collapse and anti-tumour activity of 5,6-dimethylxanthenone-4-acetic acid.
Anticancer research 1998;18(6A):4409-13.
1998: Bruce C Baguley; Lynnette Ferguson
Mutagenic properties of topoisomerase-targeted drugs.
Biochimica et biophysica acta 1998;1400(1-3):213-22.
1998: C J Lash; A E Li; Michael D Rutland; Bruce C Baguley; L Jonathan Zwi; William Wilson
Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs.
British journal of cancer 1998;78(4):439-45.
1998: Lai-Ming Ching; WL Browne; R Tchernegovski; T Gregory; Bruce C Baguley; Brian Palmer
Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid: concomitant reduction of serum tumour necrosis factor-alpha and enhancement of anti-tumour activity.
British journal of cancer 1998;78(3):336-43.
1998: J H Pang; Z Cao; Wayne R Joseph; Bruce C Baguley; Lai-Ming Ching
Antitumour activity of the novel immune modulator 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice lacking the interferon-gamma receptor.
European journal of cancer (Oxford, England : 1990) 1998;34(8):1282-9.
1998: Bruce C Baguley; Elaine S Marshall; KM Holdaway; Gordon W Rewcastle; William A Denny
Inhibition of growth of primary human tumour cell cultures by a 4-anilinoquinazoline inhibitor of the epidermal growth factor receptor family of tyrosine kinases.
European journal of cancer (Oxford, England : 1990) 1998;34(7):1086-90.
1997: Nicole J Moreland; Graeme J Finlay; M Dragunow; KM Holdaway; Bruce C Baguley
Cellular responses to methyl-N-[4-9-acridinylamino)-2-methoxyphenyl] carbamate hydrochloride, an analogue of amsacrine active against non-proliferating cells.
European journal of cancer (Oxford, England : 1990) 1997;33(10):1668-76.
1997: Bruce C Baguley; L M Ching
Immunomodulatory actions of xanthenone anticancer agents.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 1997;8(2):119-27.
1997: Julie A Spicer; Swarna A Gamage; Graham J Atwell; Graeme J Finlay; Bruce C Baguley; William A Denny
Structure-activity relationships for acridine-substituted analogues of the mixed topoisomerase I/II inhibitor N-[2-(dimethylamino)ethyl]acridine-4-carboxamide.
Journal of medicinal chemistry 1997;40(12):1919-29.
1997: JY Fan; K K Valu; P D Woodgate; Bruce C Baguley; William A Denny
Aniline mustard analogues of the DNA-intercalating agent amsacrine: DNA interaction and biological activity.
Anti-cancer drug design 1997;12(3):181-203.
1997: Bruce C Baguley; F Leteurtre; J F Riou; Graeme J Finlay; Y Pommier
A carbamate analogue of amsacrine with activity against non-cycling cells stimulates topoisomerase II cleavage at DNA sites distinct from those of amsacrine.
European journal of cancer (Oxford, England : 1990) 1997;33(2):272-9.
1997: David J Bridewell; Graeme J Finlay; Bruce C Baguley
Differential actions of aclarubicin and doxorubicin: the role of topoisomerase I.
Oncology research 1997;9(10):535-42.
1997: Martin Philpott; Wayne R Joseph; Kathryn E Crosier; Bruce C Baguley; Lai-Ming Ching
Production of tumour necrosis factor-alpha by cultured human peripheral blood leucocytes in response to the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (NSC 640488).
British journal of cancer 1997;76(12):1586-91.
1997: Bruce C Baguley; L Zhuang; Philip Kestell
Increased plasma serotonin following treatment with flavone-8-acetic acid, 5,6-dimethylxanthenone-4-acetic acid, vinblastine, and colchicine: relation to vascular effects.
Oncology research 1997;9(2):55-60.
1996: Lynnette Ferguson; Bruce C Baguley
Mutagenicity of anticancer drugs that inhibit topoisomerase enzymes.
Mutation research 1996;355(1-2):91-101.
1996: Graeme J Finlay; J F Riou; Bruce C Baguley
From amsacrine to DACA (N-[2-(dimethylamino)ethyl]acridine-4-carboxamide): selectivity for topoisomerases I and II among acridine derivatives.
European journal of cancer (Oxford, England : 1990) 1996;32A(4):708-14.
1996: Lynnette Ferguson; G Whiteside; K M Holdaway; Bruce C Baguley
Application of fluorescence in situ hybridisation to study the relationship between cytotoxicity, chromosome aberrations, and changes in chromosome number after treatment with the topoisomerase II inhibitor amsacrine.
Environmental and molecular mutagenesis 1996;27(4):255-62.
1995: Bruce C Baguley; Graeme J Finlay
Pharmacokinetic/cytokinetic principles in the chemotherapy of solid tumours.
Clinical and experimental pharmacology & physiology 1995;22(11):825-8.
1995: Lai-Ming Ching; Z F Xu; B H Gummer; Brian Palmer; Wayne R Joseph; Bruce C Baguley
Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxanthenone-4-acetic acid.
British journal of cancer 1995;72(2):339-43.
1995: Graham J Atwell; B M Yaghi; PR Turner; M Boyd; C J O'Connor; Lynnette Ferguson; Bruce C Baguley; W A Denny
Synthesis, DNA interactions and biological activity of DNA minor groove targeted polybenzamide-linked nitrogen mustards.
Bioorganic & medicinal chemistry 1995;3(6):679-91.
1995: Bruce C Baguley; L Zhuang; Elaine S Marshall
Experimental solid tumour activity of N-[2-(dimethylamino)ethyl]-acridine-4-carboxamide.
Cancer chemotherapy and pharmacology 1995;36(3):244-8.
1995: M Philpott; Bruce C Baguley; Lai-Ming Ching
Induction of tumour necrosis factor-alpha by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid.
Cancer chemotherapy and pharmacology 1995;36(2):143-8.
1995: Bruce C Baguley; Elaine S Marshall; J R Whittaker; M C Dotchin; J Nixon; MR McCrystal; Graeme J Finlay; J H Matthews; K M Holdaway; P van Zijl
Resistance mechanisms determining the in vitro sensitivity to paclitaxel of tumour cells cultured from patients with ovarian cancer.
European journal of cancer (Oxford, England : 1990) 1995;31A(2):230-7.
1995: E Veszelovsky; N H Holford; L L Thomsen; R G Knowles; Bruce C Baguley
Plasma nitrate clearance in mice: modeling of the systemic production of nitrate following the induction of nitric oxide synthesis.
Cancer chemotherapy and pharmacology 1995;36(2):155-9.
1994: G L Gravatt; Bruce C Baguley; William Wilson; W A Denny
DNA-directed alkylating agents. 6. Synthesis and antitumor activity of DNA minor groove-targeted aniline mustard analogues of pibenzimol (Hoechst 33258)
Journal of medicinal chemistry 1994;37(25):4338-45.
1994: Philip Kestell; Gordon W Rewcastle; Bruce C Baguley
Disposition of the novel antitumour agent xanthenone-4-acetic acid in the mouse: identification of metabolites and routes of elimination.
Xenobiotica; the fate of foreign compounds in biological systems 1994;24(7):635-47.
1994: S Cliffe; M L Taylor; Michael D Rutland; Bruce C Baguley; R P Hill; William Wilson
Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid.
International journal of radiation oncology, biology, physics 1994;29(2):373-7.
1994: L Jonathan Zwi; Bruce C Baguley; J B Gavin; William Wilson
The morphological effects of the anti-tumor agents flavone acetic acid and 5,6-dimethyl xanthenone acetic acid on the colon 38 mouse tumor.
Pathology 1994;26(2):161-9.
1994: Lai-Ming Ching; Wayne R Joseph; Kathryn E Crosier; Bruce C Baguley
Induction of tumor necrosis factor-alpha messenger RNA in human and murine cells by the flavone acetic acid analogue 5,6-dimethylxanthenone-4-acetic acid (NSC 640488).
Cancer research 1994;54(4):870-2.
1994: Graeme J Finlay; K M Holdaway; Bruce C Baguley
Novel carbamate analogues of amsacrine with activity against non-cycling murine and human tumour cells.
Cancer chemotherapy and pharmacology 1994;34(2):159-65.
1994: Elaine S Marshall; J H Matthews; J H Shaw; J Nixon; P Tumewu; Graeme J Finlay; K M Holdaway; Bruce C Baguley
Radiosensitivity of new and established human melanoma cell lines: comparison of [3H]thymidine incorporation and soft agar clonogenic assays.
European journal of cancer (Oxford, England : 1990) 1994;30A(9):1370-6.
1994: Lai-Ming Ching; Wayne R Joseph; L Zhuang; Bruce C Baguley
Interaction between endotoxin and the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in the induction of tumour necrosis factor and haemorrhagic necrosis of colon 38 tumours.
Cancer chemotherapy and pharmacology 1994;35(2):153-60.
1994: L Jonathan Zwi; Bruce C Baguley; J B Gavin; William Wilson
Correlation between immune and vascular activities of xanthenone acetic acid antitumor agents.
Oncology research 1994;6(2):79-85.
1994: Graeme J Finlay; K M Holdaway; Bruce C Baguley
Comparison of the effects of genistein and amsacrine on leukemia cell proliferation.
Oncology research 1994;6(1):33-7.
1994: Lynnette Ferguson; Bruce C Baguley
Topoisomerase II enzymes and mutagenicity.
Environmental and molecular mutagenesis 1994;24(4):245-61.
1993: Lai-Ming Ching; Wayne R Joseph; Bruce C Baguley
Effect of tumour growth on the macrophage response to the antitumour agent 5,6-dimethylxanthenone-4-acetic acid.
Anticancer research 1993;13(6A):2069-75.
1993: Lynnette Ferguson; PM Turner; Bruce C Baguley
Induction of mitotic crossing-over by the topoisomerase II poison DACA (N-[2-dimethylamino)ethyl]acridine-4-carboxamide) in Saccharomyces cerevisiae.
Mutation research 1993;289(2):157-63.
1993: Lai-Ming Ching; Wayne R Joseph; Bruce C Baguley
Inhibition of antitumor effects of flavone acetic acid by cortisone.
Anticancer research 1993;13(4):1139-41.
1993: E Veszelovszky; L L Thomsen; Z Li; Bruce C Baguley
Flavone acetic acid and 5,6-dimethylxanthenone-4-acetic acid: relationship between plasma nitrate elevation and the induction of tumour necrosis.
European journal of cancer (Oxford, England : 1990) 1993;29A(3):404-8.
1993: Graeme J Finlay; Elaine S Marshall; J H Matthews; K D Paull; Bruce C Baguley
In vitro assessment of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide, a DNA-intercalating antitumour drug with reduced sensitivity to multidrug resistance.
Cancer chemotherapy and pharmacology 1993;31(5):401-6.
1993: Bruce C Baguley; G Cole; L L Thomsen; Z Li
Serotonin involvement in the antitumour and host effects of flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid.
Cancer chemotherapy and pharmacology 1993;33(1):77-81.
1993: A Haldane; Graeme J Finlay; Bruce C Baguley
A comparison of the effects of aphidicolin and other inhibitors on topoisomerase II-directed cytotoxic drugs.
Oncology research 1993;5(3):133-8.
1993: A Haldane; K M Holdaway; Graeme J Finlay; Bruce C Baguley
Cytokinetic differences in the action of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide as compared with that of amsacrine and doxorubicin.
Cancer chemotherapy and pharmacology 1993;32(6):463-70.
1993: Elaine S Marshall; K M Holdaway; J H Shaw; Graeme J Finlay; J H Matthews; Bruce C Baguley
Anticancer drug sensitivity profiles of new and established melanoma cell lines.
Oncology research 1993;5(8):301-9.
1993: Lynnette Ferguson; Bruce C Baguley
Multidrug resistance and mutagenesis.
Mutation research 1993;285(1):79-90.
1992: L L Thomsen; Bruce C Baguley; G J Rustin; S M O'Reilly
Flavone acetic acid (FAA) with recombinant interleukin-2 (TIL-2) in advanced malignant melanoma. II: Induction of nitric oxide production.
British journal of cancer 1992;66(4):723-7.
1992: Swarna A Gamage; Gordon W Rewcastle; Graham J Atwell; Bruce C Baguley; W A Denny
Structure-activity relationships for substituted 9-oxo-9,10-dihydroacridine-4-acetic acids: analogues of the colon tumour active agent xanthenone-4-acetic acid.
Anti-cancer drug design 1992;7(5):403-14.
1992: Brian Palmer; G Wickham; D J Craik; W David McFadyen; L P Wakelin; Bruce C Baguley; W A Denny
Synthesis, DNA binding interactions and biological activity of bis platinum (II) complexes of N,N,N',N'-tetrakis(2-aminoethyl)diamines.
Anti-cancer drug design 1992;7(5):385-401.
1992: H H Lee; Brian Palmer; Bruce C Baguley; M Chin; W David McFadyen; G Wickham; D Thorsbourne-Palmer; L P Wakelin; W A Denny
DNA-directed alkylating agents. 5. Acridinecarboxamide derivatives of (1,2-diaminoethane)dichloroplatinum(II).
Journal of medicinal chemistry 1992;35(16):2983-7.
1992: Lai-Ming Ching; Wayne R Joseph; Bruce C Baguley
Stimulation of macrophage tumouricidal activity by 5,6-dimethyl-xanthenone-4-acetic acid, a potent analogue of the antitumour agent flavone-8-acetic acid.
Biochemical pharmacology 1992;44(1):192-5.
1992: Lai-Ming Ching; Wayne R Joseph; Bruce C Baguley
Antitumour responses to flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid in immune deficient mice.
British journal of cancer 1992;66(1):128-30.
1992: Y Iwamoto; Lynnette Ferguson; A Pearson; Bruce C Baguley
Photo-enhancement of the mutagenicity of 9-anilinoacridine derivatives related to the antitumour agent amsacrine.
Mutation research 1992;268(1):35-41.
1992: L L Thomsen; Lai-Ming Ching; Wayne R Joseph; Bruce C Baguley; J B Gavin
Nitric oxide production in endotoxin-resistant C3H/HeJ mice stimulated with flavone-8-acetic acid and xanthenone-4-acetic acid analogues.
Biochemical pharmacology 1992;43(11):2401-6.
1992: Elaine S Marshall; Graeme J Finlay; J H Matthews; J H Shaw; J Nixon; Bruce C Baguley
Microculture-based chemosensitivity testing: a feasibility study comparing freshly explanted human melanoma cells with human melanoma cell lines.
Journal of the National Cancer Institute 1992;84(5):340-5.
1992: H H Lee; Brian Palmer; M Boyd; Bruce C Baguley; W A Denny
Potential antitumor agents. 64. Synthesis and antitumor evaluation of dibenzo[1,4]dioxin-1-carboxamides: a new class of weakly binding DNA-intercalating agents.
Journal of medicinal chemistry 1992;35(2):258-66.
1992: L L Thomsen; Bruce C Baguley; Lai-Ming Ching; J B Gavin
Modulation of superoxide production from murine macrophages by the antitumour agent flavone acetic acid and xanthenone acetic acid analogues.
Biochemical pharmacology 1992;43(2):386-9.
1992: A Haldane; Graeme J Finlay; J B Gavin; Bruce C Baguley
Unusual dynamics of killing of cultured Lewis lung cells by the DNA-intercalating antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide.
Cancer chemotherapy and pharmacology 1992;29(6):475-9.
1992: K M Holdaway; Graeme J Finlay; Bruce C Baguley
Relationship of cell cycle parameters to in vitro and in vivo chemosensitivity for a series of Lewis lung carcinoma lines.
European journal of cancer (Oxford, England : 1990) 1992;28A(8-9):1427-31.
1992: L Jonathan Zwi; Bruce C Baguley; J B Gavin; K M Holdaway; William Wilson
The role of immune effector cells in flavone acetic acid-induced injury to tumor cells in EMT6 spheroids.
Oncology research 1992;4(8-9):333-9.
1992: L L Thomsen; Bruce C Baguley; William Wilson
Nitric oxide: its production in host-cell-infiltrated EMT6 spheroids and its role in tumour cell killing by flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid.
Cancer chemotherapy and pharmacology 1992;31(2):151-5.
1992: Bruce C Baguley; Graeme J Finlay; Lai-Ming Ching
Resistance mechanisms to topoisomerase poisons: the application of cell culture methods.
Oncology research 1992;4(7):267-74.
1991: Lynnette Ferguson; PM Turner; Bruce C Baguley
Stimulation of bacterial mutagenicity by inhibitors of mammalian cell multidrug resistance.
Mutation research 1991;264(4):231-4.
1991: Bruce C Baguley
Topoisomerases and cancer treatment.
The New Zealand medical journal 1991;104(924):491-3.
1991: Gordon W Rewcastle; Graham J Atwell; Bruce C Baguley; M Boyd; L L Thomsen; L Zhuang; W A Denny
Potential antitumor agents. 63. Structure-activity relationships for side-chain analogues of the colon 38 active agent 9-oxo-9H-xanthene-4-acetic acid.
Journal of medicinal chemistry 1991;34(9):2864-70.
1991: G L Gravatt; Bruce C Baguley; William Wilson; W A Denny
DNA-directed alkylating agents. 4. 4-anilinoquinoline-based minor groove directed aniline mustards.
Journal of medicinal chemistry 1991;34(5):1552-60.
1991: Philip Kestell; Mark J McKeage; Bruce C Baguley
Determination of xanthenone-4-acetic acid in mouse plasma by high-performance liquid chromatography.
Journal of chromatography 1991;564(1):315-21.
1991: Bruce C Baguley
DNA intercalating anti-tumour agents.
Anti-cancer drug design 1991;6(1):1-35.
1991: Gordon W Rewcastle; Graham J Atwell; Brian Palmer; P D Boyd; Bruce C Baguley; W A Denny
Potential antitumor agents. 62. Structure-activity relationships for tricyclic compounds related to the colon tumor active drug 9-oxo-9H-xanthene-4-acetic acid.
Journal of medicinal chemistry 1991;34(2):491-6.
1991: Gordon W Rewcastle; Graham J Atwell; Z A Li; Bruce C Baguley; W A Denny
Potential antitumor agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids.
Journal of medicinal chemistry 1991;34(1):217-22.
1991: L L Thomsen; Lai-Ming Ching; L Zhuang; J B Gavin; Bruce C Baguley
Tumor-dependent increased plasma nitrate concentrations as an indication of the antitumor effect of flavone-8-acetic acid and analogues in mice.
Cancer research 1991;51(1):77-81.
1991: Lai-Ming Ching; Mark J McKeage; Wayne R Joseph; Philip Kestell; L Jonathan Zwi; Bruce C Baguley
Haematological effects in mice of the antitumour agents xanthenone-4-acetic acid, 5,6-dimethyl-xanthenone-4-acetic acid [correction of 5,6-methyl-] and flavone acetic acid.
Cancer chemotherapy and pharmacology 1991;28(6):414-9.
1991: Mark J McKeage; Philip Kestell; W A Denny; Bruce C Baguley
Plasma pharmacokinetics of the antitumour agents 5,6-dimethylxanthenone-4-acetic acid, xanthenone-4-acetic acid and flavone-8-acetic acid in mice.
Cancer chemotherapy and pharmacology 1991;28(6):409-13.
1991: Bruce C Baguley; K M Holdaway; L L Thomsen; L Zhuang; L Jonathan Zwi
Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism.
European journal of cancer (Oxford, England : 1990) 1991;27(4):482-7.
1991: Lai-Ming Ching; Wayne R Joseph; L Zhuang; Graham J Atwell; Gordon W Rewcastle; W A Denny; Bruce C Baguley
Induction of natural killer activity by xanthenone analogues of flavone acetic acid: relation with antitumour activity.
European journal of cancer (Oxford, England : 1990) 1991;27(1):79-83.
1991: Lai-Ming Ching; Graeme J Finlay; Wayne R Joseph; Bruce C Baguley
In vitro methods for screening agents with an indirect mechanism of antitumour activity: xanthenone analogues of flavone acetic acid.
European journal of cancer (Oxford, England : 1990) 1991;27(12):1684-9.
1991: Vernon J Harvey; J R Hardy; S Smith; W Grove; Bruce C Baguley
Phase II study of the amsacrine analogue CI-921 (NSC 343499) in non-small cell lung cancer.
European journal of cancer (Oxford, England : 1990) 1991;27(12):1617-20.
1990: L Jonathan Zwi; Bruce C Baguley; J B Gavin; William Wilson
Necrosis in non-tumour tissues caused by flavone acetic acid and 5,6-dimethyl xanthenone acetic acid.
British journal of cancer 1990;62(6):932-4.
1990: K K Valu; T A Gourdie; T J Boritzki; G L Gravatt; Bruce C Baguley; William Wilson; L P Wakelin; P D Woodgate; W A Denny
DNA-directed alkylating agents. 3. Structure-activity relationships for acridine-linked aniline mustards: consequences of varying the length of the linker chain.
Journal of medicinal chemistry 1990;33(11):3014-9.
1990: Brian Palmer; H H Lee; P Johnson; Bruce C Baguley; G Wickham; L P Wakelin; W David McFadyen; W A Denny
DNA-directed alkylating agents. 2. Synthesis and biological activity of platinum complexes linked to 9-anilinoacridine.
Journal of medicinal chemistry 1990;33(11):3008-14.
1990: L L Thomsen; Lai-Ming Ching; Bruce C Baguley
Evidence for the production of nitric oxide by activated macrophages treated with the antitumor agents flavone-8-acetic acid and xanthenone-4-acetic acid.
Cancer research 1990;50(21):6966-70.
1990: L Jonathan Zwi; Bruce C Baguley; J B Gavin; William Wilson
The use of vascularised spheroids to investigate the action of flavone acetic acid on tumour blood vessels.
British journal of cancer 1990;62(2):231-7.
1990: Graham J Atwell; Gordon W Rewcastle; Bruce C Baguley; W A Denny
Potential antitumor agents. 60. Relationships between structure and in vivo colon 38 activity for 5-substituted 9-oxoxanthene-4-acetic acids.
Journal of medicinal chemistry 1990;33(5):1375-9.
1990: Graeme J Finlay; Bruce C Baguley; K Snow; W Judd
Multiple patterns of resistance of human leukemia cell sublines to amsacrine analogues.
Journal of the National Cancer Institute 1990;82(8):662-7.
1990: T A Gourdie; K K Valu; G L Gravatt; T J Boritzki; Bruce C Baguley; L P Wakelin; William Wilson; P D Woodgate; W A Denny
DNA-directed alkylating agents. 1. Structure-activity relationships for acridine-linked aniline mustards: consequences of varying the reactivity of the mustard.
Journal of medicinal chemistry 1990;33(4):1177-86.
1990: Bruce C Baguley
The possible role of electron-transfer complexes in the antitumour action of amsacrine analogues.
Biophysical chemistry 1990;35(2-3):203-12.
1990: Gordon W Rewcastle; Philip Kestell; Bruce C Baguley; W A Denny
Light-induced breakdown of flavone acetic acid and xanthenone analogues in solution.
Journal of the National Cancer Institute 1990;82(6):528-9.
1990: Bruce C Baguley; K M Holdaway; L M Fray
Design of DNA intercalators to overcome topoisomerase II-mediated multidrug resistance.
Journal of the National Cancer Institute 1990;82(5):398-402.
1990: Philip Kestell; James W Paxton; P C Evans; D Young; J L Jurlina; I G Robertson; Bruce C Baguley
Disposition of amsacrine and its analogue 9-([2-methoxy-4-[(methylsulfonyl)amino]phenyl]amino)-N,5-dimethyl-4- acridinecarboxamide (CI-921) in plasma, liver, and Lewis lung tumors in mice.
Cancer research 1990;50(3):503-8.
1990: W A Denny; Gordon W Rewcastle; Bruce C Baguley
Potential antitumor agents. 59. Structure-activity relationships for 2-phenylbenzimidazole-4-carboxamides, a new class of "minimal" DNA-intercalating agents which may not act via topoisomerase II.
Journal of medicinal chemistry 1990;33(2):814-9.
1990: Lynnette Ferguson; C M Hill; Bruce C Baguley
Genetic toxicology of tricyclic carboxamides, a new class of DNA binding antitumour agent.
European journal of cancer (Oxford, England : 1990) 1990;26(6):709-14.
1990: Bruce C Baguley; PM Turner; Lynnette Ferguson
Protection by inhibitors of multidrug resistance against mitochondrial mutagenesis in Saccharomyces cerevisiae.
European journal of cancer (Oxford, England : 1990) 1990;26(1):55-60.
1990: Lai-Ming Ching; Graeme J Finlay; Wayne R Joseph; Bruce C Baguley
Comparison of the cytotoxicity of amsacrine and its analogue CI-921 against cultured human and mouse bone marrow tumour cells.
European journal of cancer (Oxford, England : 1990) 1990;26(1):49-54.
1990: Graeme J Finlay; Bruce C Baguley
Potentiation by phenylbisbenzimidazoles of cytotoxicity of anticancer drugs directed against topoisomerase II.
European journal of cancer (Oxford, England : 1990) 1990;26(5):586-9.
1989: Graeme J Finlay; William Wilson; Bruce C Baguley
Chemoprotection by 9-aminoacridine derivatives against the cytotoxicity of topoisomerase II-directed drugs.
European journal of cancer & clinical oncology 1989;25(12):1695-701.
1989: Lai-Ming Ching; Bruce C Baguley
Hyporesponsiveness of macrophages from C3H/HeJ (endotoxin-resistant) mice to the antitumour agent flavone acetic acid (NSC 347512).
European journal of cancer & clinical oncology 1989;25(10):1513-5.
1989: D T Liley; P M Wiggins; Bruce C Baguley
Localization of a nonintercalative DNA binding antitumour drug in mitochondria: relationship to multidrug resistance.
European journal of cancer & clinical oncology 1989;25(9):1287-93.
1989: Graham J Atwell; Gordon W Rewcastle; Bruce C Baguley; W A Denny
Synthesis and anti-tumour activity of topologically-related analogues of flavoneacetic acid.
Anti-cancer drug design 1989;4(2):161-9.
1989: L Jonathan Zwi; Bruce C Baguley; J B Gavin; William Wilson
Blood flow failure as a major determinant in the antitumor action of flavone acetic acid.
Journal of the National Cancer Institute 1989;81(13):1005-13.
1989: Lai-Ming Ching; Bruce C Baguley
Reduction of cytotoxic effector cell activity in colon 38 tumours following treatment with flavone acetic acid.
European journal of cancer & clinical oncology 1989;25(7):1061-5.
1989: Lai-Ming Ching; Bruce C Baguley
Effect of flavone acetic acid (NSC 347,512) on splenic cytotoxic effector cells and their role in tumour necrosis.
European journal of cancer & clinical oncology 1989;25(5):821-8.
1989: Gordon W Rewcastle; Graham J Atwell; Bruce C Baguley; S B Calveley; W A Denny
Potential antitumor agents. 58. Synthesis and structure-activity relationships of substituted xanthenone-4-acetic acids active against the colon 38 tumor in vivo.
Journal of medicinal chemistry 1989;32(4):793-9.
1989: Graham J Atwell; Bruce C Baguley; W A Denny
Potential antitumor agents. 57. 2-Phenylquinoline-8-carboxamides as "minimal" DNA-intercalating antitumor agents with in vivo solid tumor activity.
Journal of medicinal chemistry 1989;32(2):396-401.
1989: Graeme J Finlay; Bruce C Baguley
Selectivity of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide towards Lewis lung carcinoma and human tumour cell lines in vitro.
European journal of cancer & clinical oncology 1989;25(2):271-7.
1989: Bruce C Baguley; S B Calveley; K K Crowe; L M Fray; S A O'Rourke; G P Smith
Comparison of the effects of flavone acetic acid, fostriecin, homoharringtonine and tumour necrosis factor alpha on colon 38 tumours in mice.
European journal of cancer & clinical oncology 1989;25(2):263-9.
1989: Lynnette Ferguson; P van Zijl; Bruce C Baguley
Mutagenicity profiles of newer amsacrine analogues with activity against solid tumours: comparison of microbial and mammalian systems.
European journal of cancer & clinical oncology 1989;25(2):255-61.
1988: J R Hardy; Vernon J Harvey; J W Paxton; P Evans; S Smith; W Grove; A J Grillo-Lopez; Bruce C Baguley
Phase I trial of the amsacrine analogue 9-[( 2-methoxy-4-[(methylsulfonyl)amino]-phenyl]amino)-N,5-dimethyl-4- acridinecarboxamide (CI-921).
Cancer research 1988;48(22):6593-6.
1988: E Schneider; S J Darkin; P A Lawson; Lai-Ming Ching; R K Ralph; Bruce C Baguley
Cell line selectivity and DNA breakage properties of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide: role of DNA topoisomerase II.
European journal of cancer & clinical oncology 1988;24(11):1783-90.
1988: Bruce C Baguley
The potential of molecular and cellular biology.
The New Zealand medical journal 1988;101(856 Pt 2):700-2.
1988: Lai-Ming Ching; Bruce C Baguley
Enhancement of in vitro cytotoxicity of mouse peritoneal exudate cells by flavone acetic acid (NSC 347512).
European journal of cancer & clinical oncology 1988;24(9):1521-5.
1988: Lynnette Ferguson; Bruce C Baguley
Verapamil as a co-mutagen in the Salmonella/mammalian microsome mutagenicity test.
Mutation research 1988;209(1-2):57-62.
1988: Graham J Atwell; C D Bos; Bruce C Baguley; W A Denny
Potential antitumor agents. 56. "Minimal" DNA-intercalating ligands as antitumor drugs: phenylquinoline-8-carboxamides.
Journal of medicinal chemistry 1988;31(5):1048-52.
1988: Graeme J Finlay; G P Smith; L M Fray; Bruce C Baguley
Effect of flavone acetic acid on Lewis lung carcinoma: evidence for an indirect effect.
Journal of the National Cancer Institute 1988;80(4):241-5.
1988: Bruce C Baguley; Graeme J Finlay
Derivatives of amsacrine: determinants required for high activity against Lewis lung carcinoma.
Journal of the National Cancer Institute 1988;80(3):195-9.
1988: Graham J Atwell; Bruce C Baguley; W A Denny
Potential antitumor agents. 55. 6-Phenylphenanthridine-4-carboxamides: a new class of DNA-intercalating antitumor agents.
Journal of medicinal chemistry 1988;31(4):774-9.
1988: Brian Palmer; Gordon W Rewcastle; Graham J Atwell; Bruce C Baguley; W A Denny
Potential antitumor agents. 54. Chromophore requirements for in vivo antitumor activity among the general class of linear tricyclic carboxamides.
Journal of medicinal chemistry 1988;31(4):707-12.
1988: Bruce C Baguley; S B Calveley; Vernon J Harvey
Effects of CI-921, an analogue of amsacrine, on advanced Lewis lung tumours in mice: relevance to clinical trials.
European journal of cancer & clinical oncology 1988;24(2):211-8.
1988: Bruce C Baguley; Graeme J Finlay
Relationship between the structure of analogues of amsacrine and their degree of cross-resistance to adriamycin-resistant P388 leukaemia cells.
European journal of cancer & clinical oncology 1988;24(2):205-10.
1988: Lynnette Ferguson; P van Zijl; Bruce C Baguley
Comparison of the mutagenicity of amsacrine with that of a new clinical analogue, CI-921.
Mutation research 1988;204(2):207-17.
1988: M A Robbie; Bruce C Baguley; W A Denny; J B Gavin; William Wilson
Mechanism of resistance of noncycling mammalian cells to 4'-(9-acridinylamino)methanesulfon-m-anisidide: comparison of uptake, metabolism, and DNA breakage in log- and plateau-phase Chinese hamster fibroblast cell cultures.
Cancer research 1988;48(2):310-9.
1988: James W Paxton; J R Hardy; P C Evans; Vernon J Harvey; Bruce C Baguley
The clinical pharmacokinetics of N-5-dimethyl-9-[(2-methoxy-4-methyl-sulfonylamino)phenylamino]-4 -acridinecarboxamide (CI-921) in a phase 1 trial.
Cancer chemotherapy and pharmacology 1988;22(3):235-40.
1988: Philip Kestell; James W Paxton; I G Robertson; P C Evans; R A Dormer; Bruce C Baguley
Thiolytic cleavage and binding of the antitumour agent CI-921 in blood.
Drug metabolism and drug interactions 1988;6(3-4):327-36.
1988: I G Robertson; Graham J Atwell; Bruce C Baguley
The relationship between lipophilic-hydrophilic balance, uptake and anti-bacteriophage lambda activity of experimental anti-tumour bisquaternary salts.
Chemico-biological interactions 1988;65(1):85-95.
1987: W A Denny; Graham J Atwell; Bruce C Baguley
'Minimal' DNA-intercalating agents as anti-tumour drugs: 2-styrylquinoline analogues of amsacrine.
Anti-cancer drug design 1987;2(3):263-70.
1987: Graeme J Finlay; William Wilson; Bruce C Baguley
Cytokinetic factors in drug resistance of Lewis lung carcinoma: comparison of cells freshly isolated from tumours with cells from exponential and plateau-phase cultures.
British journal of cancer 1987;56(6):755-62.
1987: W A Denny; Bruce C Baguley
Amsacrine analogues with extended chromophores: DNA binding and anti-tumour activity.
Anti-cancer drug design 1987;2(1):61-70.
1987: Lai-Ming Ching; Bruce C Baguley
Induction of natural killer cell activity by the antitumour compound flavone acetic acid (NSC 347 512).
European journal of cancer & clinical oncology 1987;23(7):1047-50.
1987: Bruce C Baguley; William Wilson
Comparison of in vivo and in vitro drug sensitivities of Lewis lung carcinoma and P388 leukaemia to analogues of amsacrine.
European journal of cancer & clinical oncology 1987;23(6):607-13.
1986: Gordon W Rewcastle; W A Denny; William Wilson; Bruce C Baguley
In vitro and in vivo assessment of activity of new anilino-substituted analogues of amsacrine against Lewis lung carcinoma.
Anti-cancer drug design 1986;1(3):215-22.
1986: W A Denny; S J Twigden; Bruce C Baguley
Steric constraints for DNA binding and biological activity in the amsacrine series.
Anti-cancer drug design 1986;1(2):125-32.